AbbVie

Open: 144.79 Close: 146.38 Change: 1.59

Don't invest in AbbVie Company Inc Stock before reading this automated analysis produce by an AI.

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, acquire, share, Cerevel, ImmunoGen, announce, Therapeutics, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie is in talks to pay around $45 per share for Cerevel Therapeutics. Cerevel will specifically beef up AbbVsies portfolio for psychiatric and neurological disorders.

Today's News

AbbVie on Wednesday said it will acquire neuroscience drugmaker Cerevel Therapeutics for roughly $8.7 billion. Under the terms of the deal, Abbvie will pay $45 per share for Cerevel. Cerevel will specifically beef up AbbVsies portfolio for psychiatric and neurological disorders. AbbVie is in talks to pay around $45 per share for Cerevel Therapeutics. The acquisition would come just days after it agreed to buy cancer drug developer ImmunoGen. AbbVie agrees $10 billion oncology acquisition. The proposed acquisition will accelerate Abbvies entry into the commercial market for ovarian cancer. AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 a share. AbbVie is buying ImmunoGen in a deal valued at about $10.1 billion with the goal of speeding the pharmaceuticals entry into the market for ovarian cancer treatments. Purchase is the largest of a Massachusetts company this year. AbbVie will acquire neuroscience-drug maker Cerevel Therapeutics Holdings for $45 a share. The deal is expected to close in the middle of 2024. AbbVie says it will buy ImmunoGen for about $10 billion, adding to a series of multi-billion dollar acquisitions built around ADCs. “We see it as a good fit for Abbvie, which needs new growth drivers,” write William Blairs Andy. AbbVie to Present at the Morgan Stanley Healthcare Conference. The company announces a major deal worth over $10 billion. AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2023. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announces a partnership with Abbvie. AbbVie announced it would acquire Irish-based Allergan plc for about $63 billion. In June, Abbvie acquired TeneoOne and its lead compound TNB-383B. In November 2023, the company announced it will be buying ImmunoGen for $10.1 billion. AbbVie is marketed by both Abbott Laboratories and Genech USA, which is a member of the European Hematology Association (EHA) On June 13, Abbvie announced results at the European HMA congress. AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 per share. The deal is expected to close sometime in the middle of 2024. AbbVie Inc. will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinsons disease (PD), and mood disorders.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

Are looking for the most relevant information about AbbVie? Investor spend a lot of time searching for information to make investment decisions in AbbVie. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, acquire, share, Cerevel, ImmunoGen, announce, Therapeutics, and the most common words in the summary are: abbvie, market, job, stock, drug, immunogen, best, . One of the sentences in the summary was: AbbVie is in talks to pay around $45 per share for Cerevel Therapeutics. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #market #job #stock #drug #immunogen #best.